Alejandro Fernandez Martell2024-09-10T10:00:58
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies, explains Alejandro Fernandez Martell and James Berrie from Lonza.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-08-20T08:43:00Z
Author Dr Daniel Tillett
2023-03-02T13:57:58
Sponsored by Cell Signaling Technology
2023-09-06T16:55:04
Sponsored by NanoTemper Technologies
2024-02-01T11:52:50
Sponsored by Leica Microsystems
2023-01-10T09:50:16
Sponsored by Sartorius Incucyte® Live-Cell Analysis System
2026-07-31T06:00:00
Contributor Dr Davinder Ramsingh, Drug Target Review
2026-08-03T06:00:00
Author Dr Xiaoxiao Wang, Yan Zhang and Junli Zhao
Site powered by Webvision Cloud